|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
A total of 50 patients with chronic lymphocytic leukaemia (CLL), as well as the B-cell leukaemia cell lines MEC-1, JVM-3, and BV-173 were studied in order to assess the incidence of CD13/aminopeptidase N (APN) immunolabelling with a monoclonal antibody 7H5 compared to LeuM7 and to CD13 mRNA levels, and to correlate these data with the cytotoxic and apoptosis-induction activity of the natural phenolic APN inhibitor curcumin.
|
22664111 |
2012 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
LHGDN |
A mutation in aminopeptidase N (CD13) isolated from a patient suffering from leukemia leads to an arrest in the endoplasmic reticulum.
|
16469741 |
2006 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A mutation in aminopeptidase N (CD13) isolated from a patient suffering from leukemia leads to an arrest in the endoplasmic reticulum.
|
16469741 |
2006 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Immunophenotyping of the first leukemia sample revealed a mixed lineage leukemia immunophenotype with positivity for terminal deoxynucleotidyl transferase (TdT), CD13 and CD19; the second sample revealed solely myeloid characteristics with positivity for CD13, CD41 and CD61, whereas TdT was negative.
|
15863212 |
2005 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, anti-CD13 monoclonal antibodies are used as diagnostic markers in leukaemia typing.
|
11260074 |
2001 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD13--not just a marker in leukemia typing.
|
10098327 |
1999 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Alanyl aminopeptidase (APN, CD13) is highly expressed in human monocytes, and anti-CD13 monoclonal antibodies are well established routine markers in leukaemia typing.
|
10373632 |
1999 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our results suggest that the leukemia with inv(3)(q21q26) represents a new cytogenetic-clinicopathologic subtype, characterized by 1) abnormal megakaryopoiesis and multiple hematopoietic lineage involvement; 2) an antecedent MDS; 3) poor response to conventional chemotherapy; and 4) expression of CD7, CD34, CD38, HLA-DR, CD13, and CD33 antigens.
|
9209472 |
1997 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
CD13/aminopeptidase N (APN) is a cell surface metallopeptidase expressed by normal and leukemic myeloid cells, and by lymphoblasts in 5-10% of acute lymphoid leukemia (ALL) cases, previously classified as 'biphenotypic' or 'mixed-lineage' leukemias.
|
7658720 |
1995 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
It is therefore intriguing from a biological standpoint why the supposedly early antigens (CD33 and CD13) remain unexpressed; this may represent an example of 'asynchronous differentiation' in leukaemia.
|
1382546 |
1992 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Surprisingly, the leukemia cells also expressed the CD13 myeloid antigen.
|
2046386 |
1991 |